Company Information
Gossamer Bio was founded on January 2015. The company is based in San Diego, CA, USA . The number of employees in Gossamer Bio is less than 250. Gossamer bio is a biopharmaceutical company focused on the discovery and development of novel and differentiated therapeutic products.Funding & investors
Gossamer Bio has received 3 rounds of venture funding. The total funding amount is around $480M.- MidCap Financial (Venture debt)
- Hillhouse Capital Group (Private equity firm)
- The Baupost Group (Hedge fund)
- Invus (Venture capital)
- ARCH Venture Partners (Venture capital)
- Contact us if you are interested to see all 10 investors
Similar Companies [beta]
- Frequency therapeutics
- 4d molecular therapeutics
- Oncorus
- Revivemed
- Twentyeight seven therapeutics
- Encoded therapeutics
- More...
Venture Categories
Active Venture Investors
- Active Investors in Biotechnology
- Active Investors in Health Care
- Active Investors in Science And Engineering
- Active Investors in Wellness
Venture Competitors
- Best Funded Biotechnology Startups
- Best Funded Health Care Startups
- Best Funded Science And Engineering Startups
- Best Funded Wellness Startups
News
Gossamer Bio - Blog
- Phase 1 Drug-Drug Interaction Studies of Inhaled Seralutinib in Healthy Subjects
- GB5121 is a Novel, Highly Potent and Selective CNS-Penetrant BTK Inhibitor for CNS Malignancies
- A phase 1, open-label study of inhaled seralutinib to assess potential effects on the pharmacokinetics (PK) of cytochrome P450 (CYP) and transporter substrates in healthy subjects
- Evidence of Target Engagement and Modulation: Biomarker Analysis of the Phase 1b Inhaled Seralutinib Study
- Phase 2 Clinical Study to Evaluate the Efficacy and Safety of Inhaled Seralutinib for the Treatment of World Health Organization Group 1 Pulmonary Arterial Hypertension
- Understanding Drivers and Barriers to Participation in Clinical Trials for Patients With Pulmonary Arterial Hypertension (PAH)
PVRI – June 2022The post Phase 1 Drug-Drug Interaction Studies of Inhaled Seralutinib in Healthy Subjects appeared first on Gossamer Bio.
EHA – June 2022The post GB5121 is a Novel, Highly Potent and Selective CNS-Penetrant BTK Inhibitor for CNS Malignancies appeared first on Gossamer Bio.
PHA – June 2022The post A phase 1, open-label study of inhaled seralutinib to assess potential effects on the pharmacokinetics (PK) of cytochrome P450 (CYP) and transporter substrates in healthy subjects appeared first on Gossamer Bio.
PHA – June 2022The post Evidence of Target Engagement and Modulation: Biomarker Analysis of the Phase 1b Inhaled Seralutinib Study appeared first on Gossamer Bio.
PHA – June 2022The post Phase 2 Clinical Study to Evaluate the Efficacy and Safety of Inhaled Seralutinib for the Treatment of World Health Organization Group 1 Pulmonary Arterial Hypertension appeared first on Gossamer Bio.
PHA – June 2022The post Understanding Drivers and Barriers to Participation in Clinical Trials for Patients With Pulmonary Arterial Hypertension (PAH) appeared first on Gossamer Bio.
Share:
